Gene expression vaccine

US7118888B2 · kind B2 · utility

Assignees

• University of South Florida Board of Trustees · US
• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Shyam S. Mohapatra · Lutz, US
• Mukesh Kumar · Tampa, US
• Shua-ku Huang · Towson, US
• Kam W. Leong · Ellicott City, US

Key dates

• Filing date: Feb 12, 2002
• Grant date: Oct 10, 2006
• Expiry date: Feb 12, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal administration with GXV results in significant induction of RSV-specific antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and IFN-γ production in the lung and splenocytes. A single dose of GXV induces a drastic reduction of viral titers.